Navigation Links
Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
Date:11/1/2011

HAYWARD, Calif., Nov. 1, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, today announced that it will be presenting data on arhalofenate, a potential best-in-class treatment for gout, at the 2011 ACR/AHP Annual Scientific Meeting on Wednesday, November 9, 2011 in Chicago, IL.  The presentation will describe the results of a pooled analysis of four Phase 2 studies in patients with type 2 diabetes, a subset of which exhibited hyperuricemia. The analysis shows that the patients experienced statistically and clinically significant reductions in serum uric acid that were fully retained in patients with mild-to-moderate renal insufficiency.  

Presentation Title: "Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes"

Session Title: Metabolic and Crystal Arthropathies II: Concurrent Session on the Anti-Gout Medications – Dosing, Adverse Effects, and Economic Burden

Date/Time:  Wednesday, November 9, 2011 from 10:15 AM - 10:30 AM CST

Location: McCormick Place Convention Center: W 474 A

About Hyperuricemia and Gout

Gout is a chronic, progressive rheumatic disease, caused by an inflammatory response to uric acid crystals deposited in joints and soft tissues as a result of excess uric acid in the blood (hyperuricemia). Elevated sUA levels cause urate crystals for form in joints triggering acute arthritic flares, chronic destructive arthropathy and formation of tophi.  According to the NHANES (2007-2008) study, the incidence of hyperuricemia in the US is over 45 million and over 8 million have progressed to a gout diagnosis.  

About Metabolex

Metabolex is a privately
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
2. Metabolex Initiates Phase 1 Trial of MBX-2982
3. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... CLARA, Calif., Feb. 18 Align Technology, Inc. (Nasdaq: ... notified of a purported declaratory judgment action filed against the ... United States District Court for the Southern District of Texas. ... 2009, but has not been served with a copy of ...
... supported entry into Company,s current Phase, ... 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: ... announced that The Journal of Urology has published ... results for the Company,s proprietary Mycobacterial Cell Wall ...
... a world-leading provider of Hosted Microsoft Exchange, presents competitive risk-proof, out-of-the-box ... ... February 18, 2009 -- SherWeb , a global leader in ... Reseller Program last week. The newly implemented program provides IT ...
... Change" Campaign Part of International Effort to Combat Rare Diseases That Collectively ... ... CA (PRWEB) February 18, 2009 -- Students at Albany High School in ... some change to help support the first annual World Rare Disease Day, ...
... Red Wine & More , ... Mount Kisco, NY (PRWEB) February 18, ... resveratrol . It,s been shown to increase the life spans of yeast, ... School and the National Institute on Aging created a stir when they ...
... Regardless of where they are born in ... for many life-threatening disorders, a remarkable public health advance of ... today by the March of Dimes.All 50 states and the ... for 21 or more of the 29 serious genetic ...
Cached Medicine News:Health News:Align Technology Asserts ClearCorrect Complaint Is Without Merit 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4Health News:SherWeb Launches Unique White Label Exchange Reseller Program 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 3Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 2Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 2Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 4
... FT is an affordable full-field, autoperimeter that includes ... least 40%. It has a small footprint and ... and easy two-button operation making it not only ... FT is the workhorse of the Paradigm family ...
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
... Gentamycin sulfate is effective against gram positive ... mycoplasma, by interfering with bacterial protein synthesis ... ribosomes. Its suggested working concentration of 50 ... mammalian cells, thereby making a gentler alternative ...
... approach to practice management, built to address the ... market. OPIE was created by practicing O&P professionals ... this field, so it thinks the way you ... anything else available. If you believe there is ...
Medicine Products: